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Background
The cytochrome P-450 1A2 (CYP1A2) enzyme accounts for 
approximately 13% of the CYP family of enzymes. (1) It metabolises
drugs and is important for drug-drug interactions. Interindividual 
di!erences in CYP1A2 phenotype and genotype result in variable 
enzyme expression and functional activity, thus can alter drug plasma
concentration. Ca!eine is largely metabolised by CYP1A2 and is o%en
used to investigate an individual’s CYP1A2 metabolic activity, (2) which
may help in drug prescription and dose adjustment to avoid toxicity or
ine$cacy. (3)
The aim of this project is to develop two protocols:
      A)  To evaluate CYP1A2 phenotype through determining salivary 
            ca!eine pharmacokinetics using a competitive ELISA.
      B)  To identify the most widely studied single nucleotide 
            polymorphism (SNP) CYP1A2*1F (SNP rs762551 A/C), with 
            polymerase chain reaction-restriction enzyme fragment length 
            polymorphism (PCR-RFLP) assay.
Once protocols have been developed, we would determine if they are
appropriate for undergraduate laboratory teaching of pharmacogenomic
concepts, i.e. how interindividual di!erences in CYP1A2 activity can
alter the pharmacokinetic parameters of ca!eine.
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Methods
Ethical approval was sought but not required, as con"rmed by the
Chair of the School of Medicine Research Ethics Committees.
Development, optimization and validation of ELISA
Competitive ELISA to measure ca!eine in saliva is based on a 
previously described protocol. (4) The concentrations of 
commercially available antibodies, ca!eine conjugated to horse-
radish peroxidase and unlabelled ca!eine were optimised for the
assay. The optimised ELISA was then validated with saliva collected
at various time intervals from ten volunteers, a%er ingestion of 
100 mg ca!eine in tablet form.
The ELISA standard curve was generated on myassays.com using
four-parameter logistic curve "t. Pharmacokinetic parameters of
ca!eine were determined; coe$cient of variation (CV) was 
calculated to evaluate precision and repeatability of the immunoassay.
Data were analysed using GraphPad Prism 7.04 and expressed as
mean ± SD.
Development of PCR-RFLP assay to determine a SNP in the CYP1A2
gene
DNA was isolated from buccal cells of three volunteers using two
commercially available DNA extraction kits. It was used for 
identi"cation of CYP1A2*1F through PCR-RFLP, and its 
association with the fast metaboliser phenotype using two published
protocols. (5-6) Two pairs of forward and reverse primers were
evaluated to identify and amplify gene segment containing the
rs762551 SNP. PCR products were digested using two restriction
enzymes speci"c for the C-allele. Fragments were analysed by
agarose gel electrophoresis.
Results
Development, optimization and validation of ca"eine competitive ELISA
The optimised ELISA allowed detection of ca!eine ranging from
0.169 ng/ml - 20.0 ng/ml in saliva. CV between days was <15%,
and <5% between replicates, indicating the ELISA had acceptable
precision and repeatability. Saliva was collected before taking the
ca!eine tablet, then at 0.5, 1, 2, 3, 5, 7, 9, 12 and 24 hours. Levels
of ca!eine from 1 to 12 hours was statistically di!erent from 
baseline at 0 hour (p = <0.05) and peaked at 1.56 ± 0.98 hours.
Large interindividual variations were observed in Cmax
(1215 ± 2927 ng/ml).
PCR-RFLP assay to determine a SNP in the CYP1A2 gene
The PCR-RFLP did not yield any restriction fragments, suggesting
all three subjects had two copies of the most common A-allele. 
Use of a control restriction enzyme, which cuts outside the SNP,
yielded fragments within the expected base pair range, demonstrating
validity of the assay. Further development of the PCR-RFLP 
protocol is required to determine CYP1A2*1F genotype.
Discussion
ELISA and CYP1A2 phenotype
Competitive ELISA, optimized and validated, is sensitive enough to
quantify salivary ca!eine; it is comparable to Carvalho’s immunoassay
(7) and a commercial ELISA kit using similar antibodies. (8) Large 
interindividual variations in Cmax and Tmax may represent di!erences
in CYP1A2 activity or that ca!eine’s pharmacokinetic may not 
accurately represent CYP1A2 metabolic activity. Further study
with a larger sample size is required.
PCR-RFLP and CYP1A2 genotype
The PCR-RFLP assay requires further optimization and a larger
sample size to identify CYP1A2*1F. In addition to the enzymes
speci"c for C-allele, those speci"c for A-allele could be used.
Are the protocols appropriate for teaching the concepts of pharmacogenomics to
undergraduate students?
The competitive ELISA o!ers a simple and inexpensive way to
quantify salivary ca!eine in a standard laboratory, making it suitable
for undergraduate laboratory teaching. During the experiments,
students can practise laboratory skills, learn the principles of ELISA,
understand pharmacokinetics and drug metabolism. Fast metabolisers
metabolise drugs quickly, resulting in drug ine$cacy; whereas drugs
may accumulate in slow metabolisers, leading to toxicity. Through
understanding the metaboliser phenotypes, drug dose can be 
adjusted accordingly for maximum e$cacy and to avoid side e!ect.
Many factors a!ect CYP1A2 phenotype, but their mechanisms and
impact are unclear. The signi"cance of di!erent genotypes on its
phenotype also has to be con"rmed. The current PCR-RFLP 
protocol is not appropriate for undergraduate laboratory and 
requires further optimization.
Lessons Learnt
Constant re#ection on the experimental process was required to
produce an optimised immunoassay for the accurate quanti"cation
of salivary ca!eine level.
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As it was the !rst time carrying out a laboratory project by myself, 
I felt quite uncertain initially. However, under the guidance of my
supervisors and reading the literature, I quickly understood and 
became more interested in laboratory research.
I was surprised by the viscosity of saliva and it was hard to pipette.
In later experiments, to minimize error in volume of saliva used, a
larger volume was pipetted and vortexed a"er each dilution. In 
addition, large interindividual di#erences were observed in ca#eine
pharmacokinetic. This may be due to saliva collection not being
monitored; the duration of saliva collection could be standardised.
Moreover, it may be accounted for by di#erences in gastric emptying.
Large volume and high density food are emptied slower, (9) which
may a#ect ca#eine absorption rate. Some volunteers fasted before
taking ca#eine tablets, whereas others did not. This increased my
understanding on the interaction between drug pharmacokinetics
and consumption of food or liquid. Mealtime and saliva collection
times should be standardized in order to minimize interference of
food in future experiments. Moreover, pharmacokinetics of ca#eine
could be a#ected by di#erences in body mass, smoking and other
drugs, which should be considered in the future.
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